Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced the presentation of three abstracts on eblasakimab at the 31st European Academy of Dermatology and Venereology Congress from September 7-10, 2022. These findings highlight eblasakimab's efficacy in treating moderate-to-severe atopic dermatitis in adult patients through randomized, double-blinded studies. The posters will address improvements in disease measures, reduction in biomarkers associated with atopy, and alleviation of itch and sleep disturbances.
ASLAN Pharmaceuticals (NASDAQ: ASLN) has announced a research collaboration with Johns Hopkins and Duke University to explore the IL-13Ra1 subunit's role in Type 2-mediated inflammatory diseases, particularly atopic dermatitis (AD). The study will assess how eblasakimab selectively targets the IL-13 receptor compared to standard treatments. Initial results are expected in late 2022. Eblasakimab is positioned as a potential first-in-class monoclonal antibody aimed at providing a differentiated safety and efficacy profile for moderate-to-severe AD, following positive Phase 1b trial results.
ASLAN Pharmaceuticals will host a final webinar in its A⁴ series on June 22, 2022, at 10:00am ET, focusing on the atopic dermatitis landscape and eblasakimab (ASLAN004). Dr. Peter A. Lio will discuss unmet medical needs in atopic dermatitis treatment, while CEO Dr. Carl Firth will share insights from market research and details about eblasakimab, currently in phase 2b trials. The session will include a live Q&A. Registration is available through ASLAN's website.
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York from June 8-10, 2022. The chat is scheduled for June 8 at 10:00 am ET. Attendees will have the opportunity for one-on-one virtual meetings with the management team. A webcast of the event will be available live and as a replay for 90 days. ASLAN is focused on developing immunology treatments, including eblasakimab for atopic dermatitis and farudodstat for autoimmune diseases.
Antibe Therapeutics Inc. (OTCQX: ATBPF) has appointed Robert E. Hoffman as the new Chair of its Board of Directors, replacing Walt Macnee. Two Vice Chair positions will be created for Macnee and Chief Scientific Officer Dr. John L. Wallace, who will remain on the Board while focusing on the company’s hydrogen sulfide platform. Hoffman, a former CFO at Heron Pharmaceuticals, brings extensive experience in pain management and capital markets. The company aims to enhance its pipeline with otenaproxesul, targeting opioid alternatives and inflammation treatment.
ASLAN Pharmaceuticals (Nasdaq: ASLN) presented new data on eblasakimab at the Society for Investigative Dermatology Annual Meeting. The study focused on neuronal itch mechanisms targeting IL-13Rα1, revealing that eblasakimab significantly reduces itch by over 40% compared to control (p=0.0001). This finding supports eblasakimab as a promising treatment for atopic dermatitis. The company previously announced positive Phase 1b results and has initiated the TREK-AD Phase 2b trial to further assess eblasakimab's safety and efficacy.
ASLAN Pharmaceuticals (NASDAQ: ASLN) will present a company update at the H.C. Wainwright Global Investment Conference from May 23 to 26, 2022. CEO Dr. Carl Firth will share insights on the company's innovative treatments targeting immunology. The presentation will be accessible starting May 24, 2022, at 7:00 AM ET for 90 days via the provided link and on ASLAN’s website. Additionally, ASLAN management is open to virtual one-on-one meetings during the conference. The company focuses on developing therapies for atopic dermatitis and autoimmune diseases.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced that an abstract regarding new data on neuronal itch mechanisms, targeting IL-13Rα1 with eblasakimab, has been accepted for a late-breaking poster presentation at the Society for Investigative Dermatology Annual Meeting, set for May 18-21, 2022, in Portland, Oregon. Dr. Ferda Cevikbas will present findings indicating that eblasakimab significantly inhibits neuronal itch responses, potentially providing a novel treatment approach for atopic dermatitis patients, which highlights the company’s focus on innovative therapies.
ASLAN Pharmaceuticals (ASLN) reported progress in its Phase 2b trial of eblasakimab for moderate-to-severe atopic dermatitis, with topline data expected in the first half of 2023. The company appointed Alex Kaoukhov as Chief Medical Officer, enhancing its leadership team. Financially, ASLN maintains a solid position with $87.4 million in cash as of March 31, 2022, despite a net loss of $12.9 million for Q1 2022, up from $6.7 million in Q1 2021. R&D expenses surged to $9.4 million, reflecting ongoing clinical development efforts.
Oak Hill Bio, a clinical-stage company focused on neonatology and rare diseases, has formed a new Board of Directors comprised of experienced leaders in life sciences. Chaired by Edwin Moses, the board's expertise spans financing, operations, drug discovery, and clinical development. Oak Hill Bio aims to advance its pipeline, including OHB-607, targeting extremely preterm infants, and OHB-101 for rare autoimmune diseases. The company is positioned to address significant unmet medical needs with its innovative therapeutics acquired from Takeda Pharmaceutical Company.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
